title: Comparison of solifenacin and fesoterodine in treatment of overactive bladder.
abstract: OBJECTIVE
  To compare the use of solifenacin and fesoterodine in treatment of overactive bladder (OAB).
  
  
  METHODS
  This prospective study was conducted on patients diagnosed with OAB who presenting to the Department of Obstetrics and Gynecology and Urology, School of Medicine, Kahramanmaraş Sütçü İmam University, Kahramanmaraş, Turkey between October 2013 and August 2014. Patients were randomized into 2 groups. Group 1 (n=60) received 5 mg solifenacin per day, while Group 2 (n=59) received 4 mg fesoterodine per day. All the patients' OAB symptom scores (OABSS) in weeks 0, 4, and 12 were recorded. In addition, treatment costs and side effects of the drugs were evaluated.
  
  
  RESULTS
  Average OABSS (score 1) was determined as: 9.5 ± 2.8 for Group 1 and 10.7 ± 1.8 for Group 2 at week 0; 2.2 ± 1.2 (Group 1) and 2.4 ± 1.3 (Group 2) at week 4 (score 2); and 1.3 ± 0.5 for Group 1 and 1.3 ± 0.6 for Group 2 at week 12 (score 3). In addition, no statistically significant difference was found between the scores (p=0.062 (score 1), p=0.464 (score 2), and p=0.527 (score 3). The discontinuation rate of medication due to its side effects was 0 (0%) for Group 1, and 6 (10.2%) for Group 2. Intragroup changes in the scores 1-2, 1-3, and 2-3 values was statistically significant in both groups (p less than 0.001).
  
  
  CONCLUSIONS
  No significant difference was found between the OABSS of these 2 drugs. However, discontinuation of drugs due to side effects was more frequent in fesoterodine.
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Kahramanmaraş Sütçü Imam University, Kahramanmaraş, Turkey. E-mail. onderdrercan@mynet.com.
authors.forename: Önder
authors.initials: Ö
authors.lastname: Ercan
authors.forename: Bülent
authors.initials: B
authors.lastname: Köstü
authors.forename: Murat
authors.initials: M
authors.lastname: Bakacak
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Aytaç-Tohma
authors.forename: Bora
authors.initials: B
authors.lastname: Çoşkun
authors.forename: Fazıl
authors.initials: F
authors.lastname: Avcı
authors.forename: Erkan
authors.initials: E
authors.lastname: Efe
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D011446:Prospective Studies; D000069464:Solifenacin Succinate / Q000627:therapeutic use*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D001559:Benzhydryl Compounds; D018727:Muscarinic Antagonists; C526675:fesoterodine; D000069464:Solifenacin Succinate